Pharma Research Bio Converts KRW 29 Billion in Bonds Into Shares

• Pharma Research Bio received conversion requests for KRW 29 billion of fourth-series convertible bonds on Oct. 22, 2026.
• Conversion at KRW 21,105 per share produces 1,374,081 shares, equivalent to 32.85% of existing shares.
• The new shares are scheduled to list on Nov. 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma Research Bio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022600650), on October 22, 2026, and is solely responsible for the information contained therein.